Result of AGM

Verici Dx PLC

25 June 2024

 

Verici Dx plc

("Verici Dx" or the "Company") 

Result of AGM and voting results

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The voting results of the AGM were as follows:

	In Favour		Against		Withheld
Resolution	Votes	%	Votes	%	Votes
1	109,919,167	97.96	2,287,678	2.04	76
2	112,096,318	99.90	110,603	0.10	0
3	112,205,310	99.99	1,611	0.01	0
4	112,081,736	99.89	125,185	0.11	0
5	112,085,956	99.89	120,965	0.11	0
6	111,792,090	99.63	414,740	0.37	91
7	112,203,528	99.99	3,233	0.01	160
8	112,192,472	99.99	14,289	0.01	160
9	112,154,800	99.95	51,921	0.05	200

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	[e-mail]
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END